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Lugano, SwitzerlandBackground The antiarrhythmic effects of n-3 polyunsaturated fatty acids (n-3PUFA) in ischemic heart disease have
been demonstrated; however, studies in patients surviving malignant ventricular arrhythmias of different etiologies treated with
an implantable cardioverter-defibrillator (ICD) have given conflicting results. The purpose of this study was to assess the
antiarrhythmic effect of n-3PUFA versus placebo in 566 patients with heart failure enrolled in the GISSI-HF trial who received an
ICD for secondary or primary prevention of ventricular fibrillation (VF) or tachycardia (VT).
Methods Clinical data and arrhythmic event recordings extracted from the device memory were obtained. We tested the
treatment effect by a multivariate Cox model adjusting for all clinical parameters associated with the primary end point defined
as time to first appropriate ICD discharge for VT/VF.
Results In the 566 patients with at least one recorded follow-up visit, 1363 VT and 316 VF episodes were terminated by
ICD pacing or shock over a median follow-up of 928 days. The incidence of the primary end point event was 27.3% in the
n-3PUFA group and 34.0% in the placebo group (adjusted hazard rate = 0.80, 95% CI 0.59-1.09, P = .152). Patients who
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rates of 11.1%, 10.7%, and 12.1% in the placebo group (overall P = .30). Patients with the highest 3-month increase in
plasma n-3PUFA had a somewhat lower incidence of arrhythmic events.
Conclusions The results of this study, though not statistically significant, support prior evidences of an antiarrhythmic
effect of n-3PUFA in patients with ICD, although they leave open the issue of whether this effect leads to a survival benefit.
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optimal medical therapy has expanded the number of
subjects who receive an ICD as backup for primary
prevention, as both treatments can be combined in the
same pacing system.2
Epidemiological studies indicate that intake of marine
long-chain n-3 polyunsaturated fatty acids (n-3PUFA) is
associated with a reduction in cardiovascular (CV)
mortality. This is supported by a number of basic studies
providing evidence that n-3PUFA reduce surrogate
markers of arrhythmia driven by Ca2+ overload.3 The
Gruppo Italiano per lo Studio della Sopravvivenza
nell'Infarto miocardico (GISSI)–Prevenzione trial found
a lower overall mortality, mostly attributable to fewer
sudden cardiac deaths among patients treated with
n-3PUFA after myocardial infarction (AMI) compared
with controls.4 GISSI-HF was the first large-scale, ran-
domized, placebo-controlled trial showing that n-3PUFA
can reduce mortality and CV hospitalization in patients
with symptomatic HF of any etiology and with any level
of LVEF.5 A recent reanalysis of GISSI-HF showed that
fatal and nonfatal ventricular arrhythmic events were
significantly reduced by n-3PUFA treatment.6 However, 3
trials in patients with an ICD implanted after malignant
ventricular tachycardia (VT) or ventricular fibrillation
(VF) of different etiology failed to demonstrate a
significant reduction of ICD interventions or of mortality
with n-3PUFA, even after pooled analysis.7-11 As a sizable
proportion of GISSI-HF patients had an ICD implanted
before or after entering the main trial, we report here the
results of a substudy, designed and conducted in parallel
to the main one, investigating the antiarrhythmic effect of
n-3PUFA in HF patients with implanted ICD.
Methods
Eighty-nine of the 325 centers participating in the GISSI-HF
trial accepted to collect an additional set of data on their clinical
history with respect to ICD management and reasons for ICD
discharge. Patients who had an ICD implanted before entering
the main trial or after randomization, either for a history of
cardiac arrest, sustained VT, or syncope of suspected tachyar-
rhythmic origin or for primary prevention, were eligible for this
substudy. Data were prospectively collected over the last period
of the study, from September 2004 to December 2007.
Study end points
The primary end points were time to an appropriate ICD
intervention for major arrhythmias, that is, shock at high or low
intensity or overdrive pacing for spontaneous ventricular
tachyarrhythmia, either VT or VF, and the number of VT and
VF episodes. Other end points were total and CV mortality,
total hospitalizations, and hospitalizations for CV events (ie,
worsening of HF, arrhythmias, and other CV causes). The ICD
data were reviewed by a central ICD Core Laboratory for
validation of arrhythmic events to rule out inappropriate ICD
electrical treatment and to characterize the detected and
treated pathologic electrograms. The clinical events recordedin the study were adjudicated blindly by an ad hoc committee
on the basis of agreed definitions and procedures. All reports
included a narrative summary with supporting documentation
for every event (eg, clinical records, death certificates, and
other relevant documentation).12
Procedures
Patients were randomly assigned to receive 1 capsule per day
of 1 g n-3PUFA (850 mg eicosapentaenoic acid and docosahex-
aenoic acid as ethyl esters in the average ratio of 1.2:1) or
matching placebo. Patients eligible for the main GISSI-HF trial
were randomized from August 6, 2002, to February 28, 2005.
Patients were scheduled for clinical visits at 1, 3, 6, and then
every 6 months until the end of the trial.
The present substudy was conducted from September 2004 to
the end of the main study, December 2007, in 89 centers. As
patients could be admitted to the ICD substudy at any time,
hospitalizations before ICD implant as well as those scheduled
for ICD implant or maintenance were discarded from the
analysis. The ICD programming was left to the cardiologist's
decision. At each follow-up visit, the ICD was interrogated by
telemetry; and the data were stored. Data from unscheduled
visits for clinical events were also collected to ensure complete
follow-up of ICD data. Blood samples for plasma levels of n-3
PUFA were obtained at baseline and after 3 months in 159 of the
566 patients enrolled in the ICD substudy.13
Statistical methods
Baseline characteristics for randomized treatments,
expressed as proportions, were compared by the χ2 test for
categorical variables and by the t test for continuous variables.
To estimate the effect of n-3PUFA on the primary end point,
univariate and multivariable Cox proportional hazards models
were fitted. Multivariable analysis was adjusted for baseline
variables that were significantly related with the outcome at
univariate analysis (P value b .05) (eg, sex, smoking, history of
atrial fibrillation, hemoglobin ≤12 g/dL, previous pacemaker,
previous ICD, previous percutaneous coronary intervention,
bundle-branch block, pulmonary rales, hematocrit, use of
direct-acting vasodilating agents). Kaplan-Meier estimates for
the time to first appropriate ICD intervention by treatment
were presented and compared by the Wilcoxon test. Time to
outcome event was computed either from the time of
randomization to the main trial, for patients implanted before
entering GISSI-HF, or from time of ICD implant, for patients
implanted during follow-up. Treatment effect was also analyzed
for secondary end points by univariate and multivariable Cox
models, adjusting for covariates associated with the outcome of
interest. Treatment effects on changes of n-3 and n-3/n-6 fatty
acids from baseline were analyzed by analysis of variance,
adjusting for their baseline value. Analyses were done with SAS
software (version 9.1; SAS, Cary, NC).
Sources of funding
The GISSI-HF main study was supported by AstraZeneca, SPA,
Pfizer, Sigma-Tau, and Pharmacia. The present substudy was
planned, conducted, and analyzed without specific financial
support by the GISSI group that has full ownership of the data, in
complete independence from the sponsors. The authors are
Table I. Baseline characteristics and treatment in the ICD substudy population and in the overall GISSI-HF study
n-3PUFA (n = 278) Placebo (n = 288) P value⁎
Overall study
(N = 6975)
Age (y), mean ± SD 64.9 ± 9.5 64.8 ± 9.8 .9149 67 ± 11
Age N70 y, n (%) 91 (32.7) 86 (30.0) .4611 2947 (42.3)
Women, n (%) 28 (10.1) 38 (13.2) .2472 1516 (21.7)
Smokers, n (%) 39 (14.0) 50 (17.4) .2763 987 (14.1)
History of hypertension, n (%) 113 (40.7) 143 (49.7) .0314 3809 (54.6)
NYHA class, n (%)
II 176 (63.3) 186 (64.6) .8033 4425 (63.4)
III 101 (36.3) 100 (34.7) 2365 (33.9)
IV 1 (0.4) 2 (0.7) 187 (2.7)
LVEF (%), mean ± SD 28.1 ± 6.5 28.7 ± 6.9 .2258 33 ± 8.5
LVEF N40%, n (%) 5 (1.8) 5 (1.7) .9550 653 (9.4)
Admission for HF in previous
year, n (%)
120 (43.2) 111 (38.5) .2632 3384 (48.5)
Previous AMI, n (%) 161 (57.9) 162 (56.2) .6893 2909 (41.7)
Stroke, n (%) 13 (4.7) 22 (7.6) .1435 346 (5.0)
Diabetes mellitus, n (%) 65 (23.4) 77 (26.7) .3574 1974 (28.3)
CABG, n (%) 74 (26.6) 82 (28.5) .6218 1271 (18.2)
PCI, n (%) 58 (20.9) 63 (21.9) .7691 866 (12.4)
ICD, n (%) 129 (46.4) 129 (44.8) .7004 497 (7.1)
Pacemaker, n (%) 62 (22.3) 68 (23.6) .7113 892 (12.8)
History of atrial fibrillation, n (%) 45 (16.2) 44 (15.3) .7664 1325 (19.0)
Peripheral vascular disease, n (%) 17 (6.1) 30 (10.4) .0637 610 (8.8)
Neoplasia, n (%) 15 (5.4) 8 (2.8) .1148 265 (3.7)
Medical treatment
ACE inhibitors, n (%) 209 (75.2) 223 (77.4) .5289 5374 (77.1)
ARBs, n (%) 64 (23.0) 55 (19.1) .2520 1321 (18.9)
ACE inhibitors/ARBs, n (%) 264 (94.7) 273 (94.8) .9259 6520 (93.5)
β-Blockers, n (%) 214 (77.0) 223 (77.4) .8980 4522 (64.8)
Spironolactone, n (%) 125 (45.0) 136 (47.2) .5900 2740 (39.3)
Diuretics, n (%) 254 (91.4) 270 (93.8) .2795 6260 (89.8)
Digitalis, n (%) 97 (34.9) 90 (31.3) .3571 2588 (37.1)
Oral anticoagulants, n (%) 110 (39.6) 102 (35.4) .3076 2009 (28.8)
Aspirin, n (%) 130 (46.8) 136 (47.2) .9128 3358 (48.1)
Other antiplatelet agents, n (%) 24 (8.6) 43 (14.9) .0204 716 (10.3)
Nitrates, n (%) 85 (30.6) 96 (33.3) .4819 2472 (35.4)
Amiodarone, n (%) 106 (38.1) 98 (34.0) .3096 1358 (19.5)
Calcium-channel blockers, n (%) 12 (4.3) 17 (6.0) .3922 709 (10.2)
Statin (open), n (%) 95 (34.17) 83 (28.8) .1703 1579 (22.6)
NYHA, New York Heart Association; AMI, acute myocardial infarction; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; ACE, angiotensin-converting
enzyme; ARB, angiotensin receptor blocker.
⁎Comparisons are between n-3PUFA and placebo groups only in the ICD substudy.
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analyses, the drafting and editing of the paper, and its final contents.Results
Patient population
Of the 566 patients with at least one recorded follow-up
visit and therefore analyzable within the GISSI-HF ICD
study, 278 were assigned to receive n-3PUFA and 288 to
placebo. Follow-up was concluded on December 31,
2007. The median follow-up duration was 928 days
(quartiles 1-3 521-1287 days). Table I shows the baseline
demographic characteristics including medical treatment
of the n-3PUFA and placebo arms of the ICD study.
Whereas no differences were observed between patients
in the treatment and placebo arms of the ICD patientpopulation, with the exception of history of hypertension
and antiplatelet use, this subgroup was younger than the
main study population and more severely ill.
At randomization, 233 patients had already an ICD
(41%); and it was implanted during the follow-up in the
other 333 (172 in placebo and 161 in n-3PUFA group).
Indications for ICD implant were secondary prevention in
27.5%, primary prevention in 56.6%, and syncope of
suspected arrhythmic etiology in 15.9% (Table II). Primary
prevention increasingly became the main indication for
implant during the study. Similarly, an increasing number
of biventricular devices with ICD backup were implanted
in 219 patients (39.0%). Baseline characteristics as well as
the effect of n-3PUFA on main outcome were similar for
patients who had a first ICD implant and those with an
ICD already present at randomization.
Table II. Indications for ICD implant by time of implant
Postrandomization
implant
n-3PUFA
(161)
Placebo
(172) P value
Syncope, n (%) 21 (13.6) 21 (12.6) .61
Primary prevention, n (%) 102 (65.8) 118 (70.7)
Secondary prevention, n (%) 32 (20.7) 28 (16.8)
CRT, n (%) 68 (42.2) 78 (46.2) .47
Prerandomization
implant
n-3PUFA
(117)
Placebo
(116) P value
Syncope, n (%) 27 (23.7) 18 (15.9) .20
Primary prevention, n (%) 40 (35.1) 51 (45.1)
Secondary prevention, n (%) 47 (41.2) 44 (38.9)
CRT, n (%) 32 (27.6) 41 (35.3) .20
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During follow-up, 174 (30.7%) patients had at least
one episode of appropriate ICD intervention. As shown
in the Kaplan-Meier curves, the incidence of ICD
interventions in the n-3PUFA group was somewhat
lower than that in the placebo group, respectively (76
[27.3%] and 98 patients [34.0%] in the placebo group;
Wilcoxon test P = .146) (Figure 1). Time to first ICD-
treated arrhythmic event showed a tendency, not
statistically significant, toward lower risk of ICD
discharge in patients treated with n-3PUFA (unadjusted
hazard rate [HR] 0.82, 95% CI 0.61-1.11, P = .210;
adjusted HR 0.80, 95% CI 0.59-1.09, P = .152).
A total of 1693 ICD-treated episodes of VT/VF were
recorded during the follow-up: 1363 (80.5%) VT, 316
(18.7%) VF, and 14 (0.8%) not defined. ICD-driven
therapy for VT episodes was recorded in 143 patients,
61 (22.0%) in the treatment group and 82 (28.5%) in the
placebo group (unadjusted HR 0.80, 95% CI 0.57-1.12,
P = .184). Patients who received 1, 2 to 3, or N3 ICD
discharges amounted to 8.9%, 7.1%, and 11.1%, respec-
tively, in n-3PUFA, as compared with 11.1%, 10.7%, and
12.1% in the placebo group (overall P = .30). ICD–driven
therapy for VF was recorded in 71 patients (12.5%), 34
(12.2%) in the treatment group and 37 (12.9%) in the
placebo group (P = .825).
When a post hoc analysis was done on the effects of
n-3PUFA by type of device implanted, treatment signifi-
cantly reduced VT/VF only in patients without CRT
(unadjusted HR 0.68, 95% CI 0.48-0.98, P = .0372),
although the interaction between treatment and type of
device was not significant (P = .32).
Secondary clinical end points
In this relatively small subgroup of patients, total
mortality was 26.6% in the n-3PUFA group and 24.3% in
the placebo group (adjusted HR 1.25, 95% CI 0.89-1.75, P =
.19). Among the other end points, the rate of CV
hospitalization tended to be lower in the treatment group(63.0%) than the placebo group (71.5%) (adjusted HR 0.87,
95% CI 0.71-1.07, P = .18), in line with the results of the
main study, although not statistically significant (Table III).
n-3PUFA plasma concentrations
Changes in n-3PUFA plasma levels from baseline to 3
months were obtained for 159 patients, 77 in the
treatment group and 82 in the placebo group. Mean ±
SD n-3PUFA plasma levels expressed as the percentage of
plasma phospholipids at baseline were 4.98 ± 1.8 in the n-
3PUFA group and 5.23 ± 1.73 in the placebo group. Mean
changes expressed as least square means were 2.23 for
the treatment group and −0.38 for the placebo group (P b
.0001). The rate of appropriate ICD interventions tended
to be lower in patients with larger 3-month increases
(ie, N0.66, median 3-month change) in plasma n-3PUFA
(26% above the median change vs 32% below, P = .405).
Discussion
In this study, we observed a nonsignificant 20%
reduction in the number of patients with appropriate
ICD interventions for VT/VF in the n-3PUFA compared
with the placebo group. This was consistent with
(a) the smaller number of patients with N1 ICD discharge,
(b) the smaller number of ICD-treated episodes, and (c)
the smaller number of arrhythmic events in subjects with
the highest plasma levels of n-3PUFA. However, results
indicate a minimal excess in total mortality in treated
patients (26.6% vs 24.3%), opposite to the results of the
main trial; on the other side, a 13% reduction in CV
hospitalization was observed. These discrepancies may
well be due to the small size of this higher-risk
subpopulation of 566 patients as compared with the
almost 7,000 patients in the main trial.
These findings are in line with experimental,14
epidemiological, and clinical studies showing a protective
effect of n-3PUFA on arrhythmias and sudden cardiac
death in the general population and in patients recover-
ing from AMI.15-18 In GISSI-HF, survival curves for total
mortality started to diverge after 2 years of treatment
because of the lack of effect of n-3PUFA on most of the
competing causes of death in HF patients, whereas the
onset of benefit of n-3PUFA on fatal and nonfatal
ventricular arrhythmias was early in post-AMI patients.4
Accordingly, the level of n-3PUFA in plasma and blood
membranes rises steeply after the start of therapy13; and
after 3 months, the plasma concentrations of n-3PUFA
had risen N45% in GISSI-HF.
To date, this is the largest study assessing the effects of
n-3PUFA in ICD patients, though with mixed indications
that may have confounded the proper assessment of n-
3PUFA antiarrhythmic effect. Accordingly, even this
relatively large study was underpowered to assess the
potential benefit. A posteriori, the statistical power to
detect a 20% reduction of appropriate ICD discharge was
40% in the present trial, whereas 2,000 patients are
Table III. Secondary end points and treatment
Secondary endpoints
n-3PUFA
(278)
Placebo
(288) Unadjusted HR (95% CI) P value Adjusted HR (95% CI) P value
Mortality 74 (26.6%) 70 (24.3%) 1.18 (0.85-1.64) .32 1.25 (0.89-1.75) .19
Mortality for worsening of HF 42 (15.1%) 45 (15.6%) 1.04 (0.68-1.59) .85 1.15 (0.75-1.78) .51
Mortality for arrhythmias 10 (3.6%) 6 (2.1%) 1.84 (0.67-5.05) .24 1.81 (0.63-5.15) .27
Hospitalization for any cause 193 (69.4%) 218 (75.7%) 0.92 (0.76-1.11) .38 0.92 (0.75-1.13) .43
Hospitalization for CV causes 175 (63.0%) 206 (71.5%) 0.88 (0.72-1.08) .21 0.87 (0.71-1.07) .18
Hospitalization for worsening of HF 110 (39.6%) 127 (44.1%) 0.95 (0.74-1.23) .71 0.96 (0.74-1.24) .72
Hospitalization for arrhythmias 48 (17.3%) 46 (16.0%) 1.12 (0.75-1.68) .58 0.98 (0.65-1.48) .92
Hospitalization for other CV causes 107 (38.5%) 127 (44.1%) 0.88 (0.68-1.14) .32 0.87 (0.67-.13) .30
Hazard ratios were calculated by using Cox univariate and multivariable models. Data are for patients who had at least one event. All analyses were based on the time to the first event.
Hospitalizations for ICD implant/maintenance and those that occurred before the ICD implant are not included.
Figure 1
Kaplan-Meier curves for the time to first appropriate ICD intervention (VT or VF) by randomized treatment. ⁎For ICD implanted during the study, the
start of follow-up date is the date of ICD implant, whereas for ICD implanted before entering GISSI-HF, the starting time corresponds to
randomization to the main trial.
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prospective randomized trial were to be planned.
So far, 3 clinical trials have been conducted in different
patient populations and using different dosages of n-
3PUFA,7-9 with contrasting results when compared.10,11
The clinical characteristics of GISSI-HF patients are
different from those of these studies. First, patients
were included on the basis of the diagnosis of HF with or
without a history of malignant ventricular arrhythmias.
Consequently, a substantial proportion of patients had an
ICD implanted for primary prevention, as recommended
by recent scientific statements and guidelines; and the
proportion rose rapidly during the trial. In contrast, all
patients in previous trials received an ICD as secondary
prevention.7-9 Primary prevention has a lower risk profilethan secondary prevention after a major ventricular
arrhythmia and/or aborted sudden death. Patients with
an indication for CRT, 39.5% of all implants, have a higher
arrhythmic risk profile than those in a better functional
status who do not need this treatment and only receive a
simple ICD device for primary prevention. In a post hoc
analysis on our study, treatment with n-3PUFA signifi-
cantly reduced time to first appropriate ICD discharge
only in patients without CRT. Although the interaction is
not statistically significant, the finding may suggest that
the more advanced disease in patients with CRT and its
proarrhythmic potential outweighed the possible protec-
tive effects of n-3PUFA.
Ischemic etiology of HF accounted only for 61.8% of
the patients as compared with 76%; mean LVEF was
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around 35%. This could indicate that, parallel to a more
compromised functional status, our patient population
had more severe ventricular arrhythmias. Overall, the
severity of HF, as expected, was higher in implanted
patients than in the whole GISSI-HF population (total
mortality of 24.3% in the placebo- and 26.6% in the n-
3PUFA–treated groups in 2 years compared with 6% to
9.4% in the other studies).7-9 The dose of n-3PUFA in
GISSI-HF was 850 mg/d, as compared with 900 to 2600
mg/d in the 3 previous studies.7-9 Although no clear
dose-effect relationship has been demonstrated, it
cannot be excluded that a higher n-3PUFA intake
might be more beneficial.
This study has several limitations. It is a substudy of the
large GISSI-HF trial with different primary end points,
whose criteria for eligibility did not include reasons for
ICD implant. However, ICD events were prospectively
collected and adjudicated by an independent commit-
tee12 of experts blind to study treatments. The trial was
conducted in 89 hospitals in the Italian National Health
system, ensuring the generalizability of its findings,
although the insufficient power of the study does not
allow definite conclusions. As during the comparatively
long period of the study there were considerable shifts in
cardiologists' attitudes in favor of the use of ICD for
primary prevention, as supported by data in Table II, and
a widespread indication for CRT with ICD back-up
protection, enrollment in this study of a majority of
patients at lower-than-expected risk profile was unavoid-
able. This could have negatively affected the possibility of
demonstrating any significant effect of n-3PUFA. Unbal-
ance between study groups in hypertension and anti-
platelet use, though unrelated to study outcome, could
have affected the results.
Conclusions
Encouraging data, in terms of reduction of sudden
cardiac death, have been shown in post-AMI and HF
patients treated with n-3PUFA. In GISSI-HF, n-3PUFA
decreased nonsignificantly the number of ICD interven-
tions for VT/VF as well as other arrhythmic events, in the
absence of a reduction in “painful shocks” and mortality.
The present study supports the trend (not statistically
significant) toward prevention of life-threatening ventric-
ular arrhythmias found in animal models and in epidemi-
ological and comparative studies.
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